Edwards Lifesciences (EW) Stock Price, News & Analysis

Company Overview

Edwards Lifesciences Corporation is a global leader in the development and commercialization of heart valve therapies and critical care monitoring. The company’s core product offerings include transcatheter and surgical heart valves used to treat a variety of valvular heart diseases, as well as systems for hemodynamic monitoring that help guide patient care in intensive care units and operating rooms. Edwards Lifesciences is particularly known for its innovations in transcatheter aortic valve replacement (TAVR) technologies, which have transformed the treatment landscape for patients with severe aortic stenosis.

Founded in 1958 as a division of Baxter International, Edwards Lifesciences pioneered the first commercially available tissue heart valve in the 1960s. The company became a standalone public entity in 2000 and has since expanded its research and development efforts to address a broader range of structural heart and critical care challenges. Edwards maintains a robust pipeline of next-generation devices and collaborates with leading academic and clinical institutions to advance minimally invasive treatment options.

Headquartered in Irvine, California, Edwards Lifesciences serves healthcare providers and patients in more than 100 countries. The company operates manufacturing facilities and research sites across North America, Europe, Asia Pacific and Latin America. With a commitment to clinical education and patient access programs, Edwards works closely with interventional cardiologists, cardiac surgeons and critical care practitioners worldwide to improve procedural outcomes and long-term patient health.

Under the leadership of Chairman and Chief Executive Officer Michael A. Mussallem, Edwards Lifesciences employs over 16,000 people dedicated to advancing cardiovascular therapy and critical care monitoring. The company’s focus on innovation, quality and clinical evidence has positioned it as a trusted partner in the global effort to address unmet needs in structural heart disease and critical care medicine.

Key Stats

• Today's Range: $77.89 to $80.45
• 50-Day Range: $75.68 to $81.76
• 52-Week Range: $64.00 to $83.00
• Volume: 3.89 million shs
• Average Volume: 4.43 million shs
• Market Capitalization: $45.98 billion
• P/E Ratio: 11.27
• Dividend Yield: N/A
• Price Target: $86.45
• Consensus Rating: Moderate Buy

Edwards Lifesciences Stock Analysis - MarketRank™

Edwards Lifesciences scored higher than 90% of companies evaluated by MarketBeat, and ranked 111th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Edwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 12 buy ratings, 9 hold ratings, and 1 sell rating.

Upside Potential

Edwards Lifesciences has a consensus price target of $86.45, representing about 10.9% upside from its current price of $77.96.

Amount of Analyst Coverage

Edwards Lifesciences has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.24%

Earnings Growth

Earnings for Edwards Lifesciences are expected to grow by 12.24% in the coming year, from $2.45 to $2.75 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Edwards Lifesciences is 11.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 279.67.

Price to Earnings Ratio vs. Sector

The P/E ratio of Edwards Lifesciences is 11.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.40.

Price to Earnings Growth Ratio

Edwards Lifesciences has a PEG Ratio of 3.87. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Edwards Lifesciences has a P/B Ratio of 4.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.42% of the float of Edwards Lifesciences has been sold short.

Short Interest Ratio / Days to Cover

Edwards Lifesciences has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edwards Lifesciences has recently increased by 1.75%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edwards Lifesciences does not currently pay a dividend.

Dividend Growth

Edwards Lifesciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -0.95

Percentage of Shares Shorted

1.42% of the float of Edwards Lifesciences has been sold short.

Short Interest Ratio / Days to Cover

Edwards Lifesciences has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edwards Lifesciences has recently increased by 1.75%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.64

News Sentiment

Edwards Lifesciences has a news sentiment score of 1.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for Edwards Lifesciences this week, compared to 24 articles on an average week.

Search Interest

Only 11 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,698,844.00 in company stock.

Percentage Held by Insiders

Only 0.34% of the stock of Edwards Lifesciences is held by insiders.

Percentage Held by Institutions

79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EW Stock Analysis - Frequently Asked Questions

How have EW shares performed this year?

Edwards Lifesciences' stock was trading at $74.03 at the beginning of the year. Since then, EW stock has increased by 5.3% and is now trading at $77.9580.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corporation (NYSE:EW) announced its quarterly earnings data on Thursday, July, 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year.
Read the conference call transcript.

When did Edwards Lifesciences' stock split?

Shares of Edwards Lifesciences split on the morning of Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were distributed to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Does Edwards Lifesciences have any subsidiaries?

Edwards Lifesciences subsidiaries include CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and more.

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' top institutional shareholders include Vanguard Group Inc. (11.92%), State Street Corp (4.37%), Bank of New York Mellon Corp (3.00%) and Geode Capital Management LLC (2.17%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Donald E Bobo Jr, Scott B Ullem, Catherine M Szyman, Daveen Chopra, Heisz Leslie Stone, Daniel J Lippis, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem.
View institutional ownership trends.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include Comcast (CMCSA), Chevron (CVX), Bristol Myers Squibb (BMY), Charles Schwab (SCHW), McKesson (MCK), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

• Last Earnings: 7/24/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 10/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:EW
• CIK: 1099800
• Web: www.edwards.com
• Phone: (949) 250-2500
• Fax: 949-250-2525
• Employees: 15,800
• Year Founded: 1958

Price Target and Rating

• Average Price Target for Edwards Lifesciences: $86.45
• High Price Target: $100.00
• Low Price Target: $60.00
• Potential Upside/Downside: +10.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.68
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.95
• Trailing P/E Ratio: 11.25
• Forward P/E Ratio: 31.89
• P/E Growth: 3.87
• Net Income: $4.17 billion
• Net Margins: 72.96%
• Pretax Margin: 28.62%
• Return on Equity: 15.01%
• Return on Assets: 11.56%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 4.68
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: $5.44 billion
• Price / Sales: 8.43
• Cash Flow: $2.66 per share
• Price / Cash Flow: 29.38
• Book Value: $17.06 per share
• Price / Book: 4.58

Miscellaneous

• Outstanding Shares: 587,100,000
• Free Float: 585,104,000
• Market Cap: $45.86 billion
• Optionable: Optionable
• Beta: 1.07